Movement Alert|PEGBIO CO-B Intraday Decline 5.26%, pullback extends after NRDL inclusion of core drug

Market Focus11-18 09:42

On November 18, PEGBIO CO-B fell 5.26% in Regular Trading, trading at HK$2.705, with turnover of HK$7.4769 million.

The latest identifiable catalyst is a continued pullback after the company’s core product Paidakang was added to the 2026 National Reimbursement Drug List, with earlier gains fading as short-term profit-taking emerged following the policy-driven rally.

Background disclosures show Paidakang, or visepegenatide injection, is the company’s once-weekly GLP-1 therapy for blood glucose control in adults with type 2 diabetes and its first approved innovative drug. The company previously entered an exclusive mainland China commercialization partnership with Shanghai Tengrui Pharmaceutical and set a cumulative sales target of more than RMB10 billion. NRDL inclusion is expected to improve affordability, hospital access, clinical promotion and market coverage, but the stock has recently turned volatile as the initial benefit was priced in.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment